Neil D. Gross, MD, FACS

home / authors / neil-d-gross-md-facs

Articles

Neil D. Gross, MD, of The University of Texas MD Anderson Cancer Cente

Dr Gross on the Neoadjuvant Utility of Cemiplimab in CSCC

Neil D. Gross, MD, FACS
June 27th 2024

Neil D. Gross, MD, FACS, discusses the neoadjuvant use of cemiplimab in the treatment of patients with cutaneous squamous cell carcinoma.

Read More

Neil D. Gross, MD, FACS

Dr Gross on the Safety of Neoadjuvant Cemiplimab in Stage II/IV CSCC

Neil D. Gross, MD, FACS
March 5th 2024

Neil D. Gross, MD, FACS, discusses key safety data from a phase 2 study of neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Read More

Neil D. Gross, MD, FACS

Dr Gross on the Background of Investigating Neoadjuvant Cemiplimab in CSCC

Neil D. Gross, MD, FACS
February 23rd 2024

Neil D. Gross, MD, FACS, discusses a phase 2 study evaluating neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Read More

Neil D. Gross, MD, FACS,

Dr Gross on Updated Survival Outcomes With Neoadjuvant Cemiplimab in CSCC

Neil D. Gross, MD, FACS
October 27th 2023

Neil D. Gross, MD, FACS, discusses 1-year follow-up data from a phase 2 study of neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Read More

Neil D. Gross, MD, FACS,

Dr. Gross on the Investigation of Cemiplimab in Cutaneous Squamous Cell Carcinoma

Neil D. Gross, MD, FACS
October 20th 2022

Neil D. Gross, MD, FACS, discusses the investigation of cemiplimab in cutaneous squamous cell carcinoma.

Read More

Dr. Gross on the Prognosis of Cutaneous Squamous Cell Carcinoma of the Head and Neck

Dr. Gross on the Prognosis of Cutaneous Squamous Cell Carcinoma of the Head and Neck

Neil D. Gross, MD, FACS
November 22nd 2019

Neil D. Gross, MD, FACS, discusses the prognosis of patients who are diagnosed with cutaneous squamous cell carcinoma of the head and neck.

Read More

Dr. Gross on Neoadjuvant Cemiplimab in Head and Neck CSCC

Dr. Gross on Neoadjuvant Cemiplimab in Head and Neck CSCC

Neil D. Gross, MD, FACS
October 12th 2019

Neil D. Gross, MD, FACS, discusses a phase II study of neoadjuvant cemiplimab in patients with stage III/IV cutaneous squamous cell carcinoma of the head and neck.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data